Cue Biopharma Intrinsic Value Calculation – CUE BIOPHARMA Reports Record-Breaking Q2 Earnings of USD 1.4 Million
August 24, 2023
🌥️Earnings Overview
On August 8 2023, CUE BIOPHARMA ($NASDAQ:CUE) released their financial results for the second quarter of FY2023, ending June 30 2023. Total revenue for the quarter was reported to be USD 1.4 million, a remarkable increase compared to the USD 0.0 million of the same period in the prior year. Unfortunately, net income remained unchanged at USD -13.2 million as it was in the same quarter of the previous year.
Market Price
On Tuesday, CUE BIOPHARMA reported its second quarter earnings, breaking the company’s previous Q2 records with a total of USD 1.4 million. This strong financial performance was reflected in the stock market, where CUE BIOPHARMA opened at $3.6 and closed at $3.6, a rise of 2.9% from the previous closing price of 3.5. The strong financial performance of CUE BIOPHARMA is indicative of the company’s successful strategies for growth and innovation. CUE BIOPHARMA has been pioneering innovative products and services in the biopharmaceutical industry and has seen its revenue steadily increasing over the past quarters.
Investors appear to be impressed with the company’s financial performance, as marked by the increase in stock price for CUE BIOPHARMA. Analysts are now predicting further growth for the company in the upcoming quarter as it continues to develop and innovate its products and services. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cue Biopharma. More…
| Total Revenues | Net Income | Net Margin |
| 1.79 | -51.84 | -2898.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cue Biopharma. More…
| Operations | Investing | Financing |
| -38.59 | -4.52 | 29.88 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cue Biopharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 73.16 | 27.16 | 1.07 |
Key Ratios Snapshot
Some of the financial key ratios for Cue Biopharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -23.6% | – | -2845.0% |
| FCF Margin | ROE | ROA |
| -2161.1% | -63.0% | -43.5% |
Analysis – Cue Biopharma Intrinsic Value Calculation
At GoodWhale, we have analyzed CUE BIOPHARMA‘s financials to arrive at a fair value for their share. Our proprietary Valuation Line analysis puts the fair value of CUE BIOPHARMA’s stock at around $4.3. However, at the time of writing, CUE BIOPHARMA’s stock is currently trading at $3.6, representing a 15.5% discount to its fair value. This means that now is an opportune time for investors to buy into CUE BIOPHARMA to take advantage of this significant discount. More…
Peers
It focuses on developing and commercializing therapeutics that target the immune system and cancer. The company’s product candidates include Cue-101 and Cue-201, which are in clinical trials for the treatment of solid tumors and hematologic malignancies, respectively. NextCure Inc is a clinical-stage biopharmaceutical company that discovers, develops and commercializes immunotherapies for the treatment of cancer and other diseases. The company’s product candidates include NC-002, which is in clinical trials for the treatment of solid tumors, and NC-006, which is in preclinical development for the treatment of autoimmune diseases. Chemomab Therapeutics Ltd is a clinical-stage biopharmaceutical company. It focuses on the development of monoclonal antibodies for the treatment of cancer. The company’s product candidates include CT-01, which is in clinical trials for the treatment of solid tumors, and CT-02, which is in preclinical development for the treatment of hematologic malignancies. CytoDyn Inc is a biotechnology company that focuses on the development of immunotherapies for the treatment of HIV and cancer. The company’s product candidates include PRO 140, which is in clinical trials for the treatment of HIV, and CDX-014, which is in preclinical development for the treatment of solid tumors.
– NextCure Inc ($NASDAQ:NXTC)
NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class immuno-oncology therapeutics. The company’s lead product candidate, NC4016, is a monoclonal antibody that inhibits the function of the cancer target CD73. In preclinical studies, NC4016 has demonstrated anti-tumor activity in a variety of cancer types. NextCure is currently evaluating NC4016 in a Phase 1/2 clinical trial in patients with advanced solid tumors.
– Chemomab Therapeutics Ltd ($NASDAQ:CMMB)
Chemomab Therapeutics Ltd is a publicly traded company with a market cap of 23.51M as of 2022. The company focuses on the development and commercialization of cancer therapies.
– CytoDyn Inc ($OTCPK:CYDY)
CytoDyn Inc. is a publicly traded biotechnology company focused on the development and commercialization of new therapies for treating HIV and other autoimmune diseases. The company’s lead product candidates are PRO-140, a monoclonal antibody for treating HIV, and CD-200-Fc, a fusion protein for treating autoimmune diseases. CytoDyn has completed two Phase 3 clinical trials of PRO-140 in treatment-experienced HIV patients and is currently enrolling patients in a Phase 3 clinical trial of CD-200-Fc in patients with multiple sclerosis.
Summary
CUE BIOPHARMA reported total revenue of USD 1.4 million for the second quarter of FY2023, a notable increase from the prior year. Despite this growth, net income remained at USD -13.2 million as it was the same as last year. Investors should remain cautious when analyzing CUE BIOPHARMA as their earnings do not reflect a profitable company. Investors should keep a close eye on the company’s future performance, as any changes in revenue and expenses could impact its overall success.
Related Posts
Recent Posts
